418 related articles for article (PubMed ID: 8261581)
1. WR2721 as a modulator of cisplatin- and carboplatin-induced side effects in comparison with other chemoprotective agents: a molecular approach.
Treskes M; van der Vijgh WJ
Cancer Chemother Pharmacol; 1993; 33(2):93-106. PubMed ID: 8261581
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
3. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate.
Treskes M; Nijtmans LG; Fichtinger-Schepman AM; van der Vijgh WJ
Biochem Pharmacol; 1992 Mar; 43(5):1013-9. PubMed ID: 1313234
[TBL] [Abstract][Full Text] [Related]
4. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
5. Effects of the modulating agent WR2721 on myelotoxicity and antitumour activity in carboplatin-treated mice.
Treskes M; Boven E; van de Loosdrecht AA; Wijffels JF; Cloos J; Peters GJ; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 1994; 30A(2):183-7. PubMed ID: 8155393
[TBL] [Abstract][Full Text] [Related]
6. Exploration of platinum-based dose-intensive chemotherapy strategies with amifostine (Ethyol).
Schuchter LM
Eur J Cancer; 1996; 32A Suppl 4():S40-2. PubMed ID: 8976821
[TBL] [Abstract][Full Text] [Related]
7. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
8. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
9. The chemical reactivity of the modulating agent WR2721 (ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin.
Treskes M; Holwerda U; Klein I; Pinedo HM; van der Vijgh WJ
Biochem Pharmacol; 1991 Nov; 42(11):2125-30. PubMed ID: 1659819
[TBL] [Abstract][Full Text] [Related]
10. BNP7787, a novel protector against platinum-related toxicities, does not affect the efficacy of cisplatin or carboplatin in human tumour xenografts.
Boven E; Verschraagen M; Hulscher TM; Erkelens CA; Hausheer FH; Pinedo HM; van der Vijgh WJ
Eur J Cancer; 2002 May; 38(8):1148-56. PubMed ID: 12008205
[TBL] [Abstract][Full Text] [Related]
11. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts.
Treskes M; Nijtmans L; Fichtinger-Schepman AM; van der Vijgh WJ
Anticancer Res; 1992; 12(6B):2261-5. PubMed ID: 1338281
[TBL] [Abstract][Full Text] [Related]
12. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
13. Cisplatin rescue therapy: experience with sodium thiosulfate, WR2721, and diethyldithiocarbamate.
Gandara DR; Wiebe VJ; Perez EA; Makuch RW; DeGregorio MW
Crit Rev Oncol Hematol; 1990; 10(4):353-65. PubMed ID: 2177606
[TBL] [Abstract][Full Text] [Related]
14. The reversal of cisplatin-protein interactions by the modulating agent WR2721 and its metabolites WR1065 and WR33278.
Treskes M; Holwerda U; Nijtmans LG; Pinedo HM; van der Vijgh WJ
Cancer Chemother Pharmacol; 1992; 29(6):467-70. PubMed ID: 1314713
[TBL] [Abstract][Full Text] [Related]
15. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
16. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
17. Carboplatin combined with amifostine, a bone marrow protectant, in the treatment of non-small-cell lung cancer: a randomised phase II study.
Betticher DC; Anderson H; Ranson M; Meely K; Oster W; Thatcher N
Br J Cancer; 1995 Dec; 72(6):1551-5. PubMed ID: 8519676
[TBL] [Abstract][Full Text] [Related]
18. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of carboplatin.
van der Vijgh WJ
Clin Pharmacokinet; 1991 Oct; 21(4):242-61. PubMed ID: 1760899
[TBL] [Abstract][Full Text] [Related]
20. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
